PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 68.11

Change

-0.25 (-0.37)%

Market Cap

N/A

Volume

4.70K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.79 (-0.54%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

-0.43 (-0.62%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-0.90 (-0.83%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.49 (-1.63%)

USD 0.20B
IDNA iShares Genomics Immunology an..

N/A

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.08 (+0.26%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-3.71 (-3.64%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.64 (-2.10%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.54 (-0.85%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.40 (-1.81%)

USD 6.67M

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.37% 29% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.37% 29% F 58% F
Trailing 12 Months  
Capital Gain 5.43% 76% C+ 52% F
Dividend Return 0.05% 13% F N/A F
Total Return 5.48% 76% C+ 40% F
Trailing 5 Years  
Capital Gain 21.76% 48% F 60% D-
Dividend Return 0.13% 11% F N/A F
Total Return 21.89% 43% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 4.90% 57% F 50% F
Dividend Return 4.92% 52% F 43% F
Total Return 0.01% 11% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 20.18% 48% F 54% F
Risk Adjusted Return 24.37% 52% F 38% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.